132 related articles for article (PubMed ID: 38401998)
1. Evidence for molecular subtyping in pancreatic ductal adenocarcinoma: a systematic review.
Robertson FP; Cameron A; Spiers HVM; Joseph N; Taylor E; Ratnayake B; Jamieson NB; Pandanaboyana S
HPB (Oxford); 2024 May; 26(5):609-617. PubMed ID: 38401998
[TBL] [Abstract][Full Text] [Related]
2. Subtype-Discordant Pancreatic Ductal Adenocarcinoma Tumors Show Intermediate Clinical and Molecular Characteristics.
Topham JT; Karasinska JM; Lee MKC; Csizmok V; Williamson LM; Jang GH; Denroche RE; Tsang ES; Kalloger SE; Wong HL; O'Kane GM; Moore RA; Mungall AJ; Notta F; Loree JM; Wilson JM; Bathe O; Tang PA; Goodwin R; Knox JJ; Gallinger S; Laskin J; Marra MA; Jones SJM; Renouf DJ; Schaeffer DF
Clin Cancer Res; 2021 Jan; 27(1):150-157. PubMed ID: 33051307
[TBL] [Abstract][Full Text] [Related]
3. Unsupervised subtyping and methylation landscape of pancreatic ductal adenocarcinoma.
Roy S; Singh AP; Gupta D
Heliyon; 2021 Jan; 7(1):e06000. PubMed ID: 33521362
[TBL] [Abstract][Full Text] [Related]
4. Clinical Impact of Molecular Subtyping of Pancreatic Cancer.
Zhou X; Hu K; Bailey P; Springfeld C; Roth S; Kurilov R; Brors B; Gress T; Buchholz M; An J; Wei K; Peccerella T; Büchler MW; Hackert T; Neoptolemos JP
Front Cell Dev Biol; 2021; 9():743908. PubMed ID: 34805152
[TBL] [Abstract][Full Text] [Related]
5. Impact of classical and basal-like molecular subtypes on overall survival in resected pancreatic cancer in the SPACIOUS-2 multicentre study.
Suurmeijer JA; Soer EC; Dings MPG; Kim Y; Strijker M; Bonsing BA; Brosens LAA; Busch OR; Groen JV; Halfwerk JBG; Slooff RAE; van Laarhoven HWM; Molenaar IQ; Offerhaus GJA; Morreau J; van de Vijver MJ; Fariña Sarasqueta A; Verheij J; Besselink MG; Bijlsma MF; Dijk F;
Br J Surg; 2022 Oct; 109(11):1150-1155. PubMed ID: 35979597
[TBL] [Abstract][Full Text] [Related]
6. Metastatic phenotype and immunosuppressive tumour microenvironment in pancreatic ductal adenocarcinoma: Key role of the urokinase plasminogen activator (PLAU).
Hosen SMZ; Uddin MN; Xu Z; Buckley BJ; Perera C; Pang TCY; Mekapogu AR; Moni MA; Notta F; Gallinger S; Pirola R; Wilson J; Ranson M; Goldstein D; Apte M
Front Immunol; 2022; 13():1060957. PubMed ID: 36591282
[TBL] [Abstract][Full Text] [Related]
7. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
8. Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes.
Zhao L; Zhao H; Yan H
BMC Cancer; 2018 May; 18(1):603. PubMed ID: 29843660
[TBL] [Abstract][Full Text] [Related]
9. Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response.
Muckenhuber A; Berger AK; Schlitter AM; Steiger K; Konukiewitz B; Trumpp A; Eils R; Werner J; Friess H; Esposito I; Klöppel G; Ceyhan GO; Jesinghaus M; Denkert C; Bahra M; Stenzinger A; Sprick MR; Jäger D; Springfeld C; Weichert W
Clin Cancer Res; 2018 Jan; 24(2):351-359. PubMed ID: 29101303
[No Abstract] [Full Text] [Related]
10. Gene expression profiling of morphologic subtypes of pancreatic ductal adenocarcinoma using surgical and EUS-FNB specimens.
Rasmussen LG; Verbeke CS; Sørensen MD; Pfeiffer P; Tan Q; Mortensen MB; Fristrup C; Detlefsen S
Pancreatology; 2021 Apr; 21(3):530-543. PubMed ID: 33637450
[TBL] [Abstract][Full Text] [Related]
11. Transcriptomic Analysis of Laser Capture Microdissected Tumors Reveals Cancer- and Stromal-Specific Molecular Subtypes of Pancreatic Ductal Adenocarcinoma.
Birnbaum DJ; Begg SKS; Finetti P; Vanderburg C; Kulkarni AS; Neyaz A; Hank T; Tai E; Deshpande V; Bertucci F; Birnbaum D; Lillemoe KD; Warshaw AL; Mino-Kenudson M; Fernandez-Del Castillo C; Ting DT; Liss AS
Clin Cancer Res; 2021 Apr; 27(8):2314-2325. PubMed ID: 33547202
[TBL] [Abstract][Full Text] [Related]
12. Tumor-intrinsic and Cancer-associated Fibroblast Subtypes Independently Predict Outcomes in Pancreatic Cancer.
Lee JJ; Kearney JF; Trembath HE; Hariharan A; LaBella ME; Kharitonova EV; Chan PS; Morrison AB; Cliff A; Meyers MO; Kim HJ; Rashid NU; Peng XL; Yeh JJ
Ann Surg; 2024 Jun; ():. PubMed ID: 38887930
[TBL] [Abstract][Full Text] [Related]
13. Stratification of Pancreatic Ductal Adenocarcinomas Based on Tumor and Microenvironment Features.
Puleo F; Nicolle R; Blum Y; Cros J; Marisa L; Demetter P; Quertinmont E; Svrcek M; Elarouci N; Iovanna J; Franchimont D; Verset L; Galdon MG; Devière J; de Reyniès A; Laurent-Puig P; Van Laethem JL; Bachet JB; Maréchal R
Gastroenterology; 2018 Dec; 155(6):1999-2013.e3. PubMed ID: 30165049
[TBL] [Abstract][Full Text] [Related]
14. The Impact of Molecular Subtyping on Pathological Staging of Pancreatic Cancer.
Dreyer SB; Rae S; Bisset K; Upstill-Goddard R; Gemenetzis G; Johns AL; Dickson EJ; Mittal A; Gill AJ; Duthie F; Pea A; Lawlor RT; Scarpa A; Salvia R; Pulvirenti A; Zerbi A; Marchesi F; McKay CJ; Biankin AV; Samra JS; Chang DK; Jamieson NB; ;
Ann Surg; 2023 Feb; 277(2):e396-e405. PubMed ID: 36745763
[TBL] [Abstract][Full Text] [Related]
15. Morphological classification of pancreatic ductal adenocarcinoma that predicts molecular subtypes and correlates with clinical outcome.
N Kalimuthu S; Wilson GW; Grant RC; Seto M; O'Kane G; Vajpeyi R; Notta F; Gallinger S; Chetty R
Gut; 2020 Feb; 69(2):317-328. PubMed ID: 31201285
[TBL] [Abstract][Full Text] [Related]
16. Bioinformatic analysis reveals pancreatic cancer molecular subtypes specific to the tumor and the microenvironment.
Le Large TY; Mato Prado M; Krell J; Bijlsma MF; Meijer LL; Kazemier G; Frampton AE; Giovannetti E
Expert Rev Mol Diagn; 2016 Jul; 16(7):733-6. PubMed ID: 27118062
[TBL] [Abstract][Full Text] [Related]
17. LMO3 is a suppressor of the basal-like/squamous subtype and reduces disease aggressiveness of pancreatic cancer through glycerol 3-phosphate metabolism.
Ohara Y; Craig AJ; Liu H; Yang S; Moreno P; Dorsey TH; Cawley H; Azizian A; Gaedcke J; Ghadimi M; Hanna N; Ambs S; Hussain SP
Carcinogenesis; 2024 Feb; ():. PubMed ID: 38366633
[TBL] [Abstract][Full Text] [Related]
18. Reciprocal regulation of pancreatic ductal adenocarcinoma growth and molecular subtype by HNF4α and SIX1/4.
Camolotto SA; Belova VK; Torre-Healy L; Vahrenkamp JM; Berrett KC; Conway H; Shea J; Stubben C; Moffitt R; Gertz J; Snyder EL
Gut; 2021 May; 70(5):900-914. PubMed ID: 32826305
[TBL] [Abstract][Full Text] [Related]
19. Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy.
Seiler R; Ashab HAD; Erho N; van Rhijn BWG; Winters B; Douglas J; Van Kessel KE; Fransen van de Putte EE; Sommerlad M; Wang NQ; Choeurng V; Gibb EA; Palmer-Aronsten B; Lam LL; Buerki C; Davicioni E; Sjödahl G; Kardos J; Hoadley KA; Lerner SP; McConkey DJ; Choi W; Kim WY; Kiss B; Thalmann GN; Todenhöfer T; Crabb SJ; North S; Zwarthoff EC; Boormans JL; Wright J; Dall'Era M; van der Heijden MS; Black PC
Eur Urol; 2017 Oct; 72(4):544-554. PubMed ID: 28390739
[TBL] [Abstract][Full Text] [Related]
20. Pacpaint: a histology-based deep learning model uncovers the extensive intratumor molecular heterogeneity of pancreatic adenocarcinoma.
Saillard C; Delecourt F; Schmauch B; Moindrot O; Svrcek M; Bardier-Dupas A; Emile JF; Ayadi M; Rebours V; de Mestier L; Hammel P; Neuzillet C; Bachet JB; Iovanna J; Dusetti N; Blum Y; Richard M; Kermezli Y; Paradis V; Zaslavskiy M; Courtiol P; Kamoun A; Nicolle R; Cros J
Nat Commun; 2023 Jun; 14(1):3459. PubMed ID: 37311751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
